Sorafenib-Daten auf dem Kongress 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO)

13. - 17. Mai 2005


Dienstag, 17. Mai:
Investoren-Telefonkonferenz ASCO Review 2005

Die Audio-Aufzeichnung dieser Veranstaltung ist nicht mehr verfügbar.

Fact Sheets und Hintergrundinformationen
(nur in Englisch verfügbar)
Sorafenib Clinical Program OverviewDownload ( PDF, 120 KB ) sammeln
Sorafenib Fact SheetDownload ( PDF, 139 KB ) sammeln
Renal Cell Carcinoma Fact SheetDownload ( PDF, 114 KB ) sammeln
Hepatocellular Carcinoma Fact SheetDownload ( PDF, 138 KB ) sammeln
Melanoma Fact SheetDownload ( PDF, 119 KB ) sammeln
Sorafenib at ASCO 2005Download ( PDF, 119 KB ) sammeln

Abstracts und Präsentationen zu Sorafenib auf dem ASCO-Meeting 2005

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: LBA4510)

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: 4544 )

A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) ( Abstract No: 5566)

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients ( Abstract No: 7508)

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma ( Abstract No: 3037)

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) ( Abstract No: 3067)

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma ( Abstract No: 3005)

Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: A prospective study ( Abstract No: 3069)

ASCO Homepage: www.asco.org

Informationen zu Klinischen Studien: www.clinicaltrials.gov

American Cancer Society: www.cancer.org

Informationen zu Nierenkrebs: www.cancer.gov/cancertopics/types/kidney

Informationen zu Leberkrebs: www.liverfoundation.org

Informationen zu Hautkrebs: www.melanomainternational.org

Informationen zu Häufigkeit, Prävalenz und Mortalität von Krebs (GLOBOCAN): www-dep.iarc.fr

Letzte Änderung: 13. Januar 2014 Copyright © Bayer AG